Quantcast

Latest Ketones Stories

2014-05-28 08:32:01

Controlled Substance Analgesic Combination Product Uses Depomed's Proprietary Acuform® Technology NEWARK, Calif., May 28, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-155. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen that has been studied for the management of moderate to...

2014-05-24 23:03:17

Vox Private Label Supplements, industry leading private label manufacturer of nutritional supplements and products, is now pre-selling order of Forskolin. Vox has sold over 125,000 bottles since May 6th. (PRWEB) May 24, 2014 #1 Leader in Forskolin Private Label Wholesale is Vox Private Label Supplements Industry leading private label supplement manufacturer, Vox Private Label Supplements, announces production increases for the supplement Forskolin. Forskolin has been in in-stock for over...

2014-05-22 23:13:15

Private Label Nutraceuticals, prominent private label contract manufacturer of nutritional supplements and products, introduces innovative weight management formulation featuring Forskolin. Atlanta, GA (PRWEB) May 22, 2014 Leading contract supplement manufacturer, Private Label Nutraceuticals announces new Forskolin product. Designed to aid in weight management, Forskolin has been added to the extensive list of stock product offerings at Private Label Nutraceuticals. Forskolin product is...

2014-05-21 08:28:20

- Rapid and effective relief for all racehorses in study MELBOURNE, Australia, May 21, 2014 /PRNewswire/ -- A Phosphagenics Limited (ASX:POH, OTCQX: PPGNY) study using its TPM(®)/Oxycodone topical patch to manage shin soreness pain for thoroughbred racehorses found recovery from pain in all horses within 1-2 days. The study was conducted on six thoroughbreds, between two and three years of age, exhibiting cannon (shin) bone soreness arising from injuries in either one or two...

2014-05-19 12:42:01

Henry Ford Health System A vast majority of so-called "super-frequent user" patients who seek care in the Emergency Department (ED) have a substance abuse addiction, according to a Henry Ford Hospital study. A patient is considered a super-frequent user who visits the ED at least 10 times a year. ED physicians have long theorized that patients who frequent the ED for their care have a substance abuse addiction. Few studies have actually measured the rate of addiction of these...

2014-05-19 08:28:11

RICHMOND, Va., May 19, 2014 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. (RBP) announced today that it has entered into a definitive agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval. The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin - a growing...

2014-05-15 08:32:25

Reckitt Benckiser Pharmaceuticals Plans to Initiate Phase II Trial of Novel Product Candidate as Potential Treatment for Alcohol Use Disorders RICHMOND, Va. and SANTA CLARA, Calif., May 15, 2014 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Reckitt Benckiser Pharmaceuticals will be granted exclusive worldwide rights for the development and commercialization of...

2014-05-13 16:29:25

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo(®) (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity....

2014-05-13 12:27:29

IPRO-designed "MAP" Tool Addresses How to Handle Numerous Patient Situations, In Order to Reduce Risk of Both Excessive Bleeding and Formation of Blood Clots LAKE SUCCESS, N.Y., May 13, 2014 /PRNewswire-USNewswire/ -- A new, free-of-charge tool designed by the Peri-Procedural Task Force of the IPRO-led New York State Anticoagulation Coalition will enable clinicians to more easily determine how, whether and when to stop the use of warfarin and other anticoagulants prior to surgery and...

2014-05-13 08:31:21

--Webcast and conference call today at 8:30 a.m. EDT-- WAYNE, Penn., May 13, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today reported business highlights and financial results for the three months ended March 31, 2014. First quarter highlights include: -- Initiated pivotal bioequivalence studies of Egalet-001; -- Received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Egalet-001, an abuse-deterrent,...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related